<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="by repurposing existing pharmaceuticals to treat illnesses other than their" exact="primary" post="indications. Here, we review current information concerning the global"/>
 <result pre="Over the past few centuries, outbreaks caused by bacteria like" exact="Yersinia pestis" post="and Vibrio cholerae (the causative agents of plague and"/>
 <result pre="few centuries, outbreaks caused by bacteria like Yersinia pestis and" exact="Vibrio cholerae" post="(the causative agents of plague and cholera, respectively, Cohn"/>
 <result pre="like Yersinia pestis and Vibrio cholerae (the causative agents of" exact="plague" post="and cholera, respectively, Cohn and Kutalek, 2016; Pechous etÂ"/>
 <result pre="and Kutalek, 2016; Pechous etÂ al., 2016) and also by" exact="viral" post="infectious agents such as influenza viruses, Ebola viruses, SARS-CoV-1,"/>
 <result pre="Kutalek, 2016; Pechous etÂ al., 2016) and also by viral" exact="infectious" post="agents such as influenza viruses, Ebola viruses, SARS-CoV-1, MERS-CoV,"/>
 <result pre="Accordingly, studying historical epidemics can help us identify patterns of" exact="viral" post="outbreaks and design a plan to prepare for the"/>
 <result pre="2018). An overview of the deadliest historical pandemics from Antonine" exact="Plague" post="in 165 CE to the ongoing COVID-19 (coronavirus disease-2019)"/>
 <result pre="from the World Health Organization (WHO) and US Centers for" exact="Disease" post="Control and Prevention, is illustrated in FigureÂ 1 and"/>
 <result pre="COVID-19 was the name that the WHO designated for the" exact="disease" post="caused by the novel coronavirus, designated 2019-nCoV and later"/>
 <result pre="caused by the novel coronavirus, designated 2019-nCoV and later severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) (Gorbalenya, 2020). Since the"/>
 <result pre="by the novel coronavirus, designated 2019-nCoV and later severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) (Gorbalenya, 2020). Since the beginning"/>
 <result pre="the novel coronavirus, designated 2019-nCoV and later severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) (Gorbalenya, 2020). Since the beginning of"/>
 <result pre="2 (SARS-CoV-2) (Gorbalenya, 2020). Since the beginning of the outbreak," exact="infections" post="have expanded rapidly into multiple simultaneous epidemics worldwide. At"/>
 <result pre="period of infectivity (Zou etÂ al., 2020), and duration of" exact="viral" post="shedding (Zhou etÂ al., 2020a) are various and uncertain."/>
 <result pre="screening provides a better picture of statistics related to asymptomatic" exact="infections" post="for epidemiologic analysis. The phylogeny, virology, and epidemiology of"/>
 <result pre="efficient treatment, precise diagnosis and classification of patients based on" exact="disease" post="severity and their probable vulnerability to COVID-19 is crucial."/>
 <result pre="diagnosis was based purely on clinical and radiographic findings (i.e.," exact="bilateral" post="infiltrates on chest imaging), failure of antibiotic therapy, and"/>
 <result pre="purely on clinical and radiographic findings (i.e., bilateral infiltrates on" exact="chest" post="imaging), failure of antibiotic therapy, and exclusion of other"/>
 <result pre="imaging), failure of antibiotic therapy, and exclusion of other common" exact="respiratory" post="infections (Huang etÂ al., 2020; Zhu et al., 2020)."/>
 <result pre="failure of antibiotic therapy, and exclusion of other common respiratory" exact="infections" post="(Huang etÂ al., 2020; Zhu et al., 2020). Now,"/>
 <result pre="2020a). Another procedure that is being used to confirm the" exact="infection" post="is monitoring laboratory features that are associated with worse"/>
 <result pre="etÂ al., 2020; Onder et al., 2020), lymphopenia, eosinopenia, elevation" exact="of liver" post="enzymes, escalation of lactate dehydrogenase, increase of inflammatory markers,"/>
 <result pre="(&amp;gt;1Â Î¼g/mL), elevated prothrombin time, elevation of troponin, increase in" exact="creatine phosphokinase" post="levels, and also acute kidney injury (Guan etÂ al.,"/>
 <result pre="elevation of troponin, increase in creatine phosphokinase levels, and also" exact="acute" post="kidney injury (Guan etÂ al., 2020). Several studies have"/>
 <result pre="of troponin, increase in creatine phosphokinase levels, and also acute" exact="kidney injury" post="(Guan etÂ al., 2020). Several studies have been conducted"/>
 <result pre="is more associated with advanced age and medical comorbidities including" exact="cardiovascular disease," post="diabetes mellitus, hypertension, chronic lung disease, cancer, and chronic"/>
 <result pre="associated with advanced age and medical comorbidities including cardiovascular disease," exact="diabetes mellitus," post="hypertension, chronic lung disease, cancer, and chronic kidney disease"/>
 <result pre="age and medical comorbidities including cardiovascular disease, diabetes mellitus, hypertension," exact="chronic" post="lung disease, cancer, and chronic kidney disease (Zhou etÂ"/>
 <result pre="and medical comorbidities including cardiovascular disease, diabetes mellitus, hypertension, chronic" exact="lung disease," post="cancer, and chronic kidney disease (Zhou etÂ al., 2020a)."/>
 <result pre="cardiovascular disease, diabetes mellitus, hypertension, chronic lung disease, cancer, and" exact="chronic" post="kidney disease (Zhou etÂ al., 2020a). Considering antihypertensive medications,"/>
 <result pre="disease, diabetes mellitus, hypertension, chronic lung disease, cancer, and chronic" exact="kidney disease" post="(Zhou etÂ al., 2020a). Considering antihypertensive medications, there are"/>
 <result pre="diabetes mellitus, hypertension, chronic lung disease, cancer, and chronic kidney" exact="disease" post="(Zhou etÂ al., 2020a). Considering antihypertensive medications, there are"/>
 <result pre="still unclear whether the high mortality rate of patients with" exact="hypertension" post="comorbidity is due to the pathology of disorder or"/>
 <result pre="(ARBs). ACE2 has been shown to be a co-receptor for" exact="viral" post="entry and pathogenesis of SARS-CoV (Li etÂ al., 2003)."/>
 <result pre="even in urine after treatment with ARBs; however, there is" exact="limited" post="evidence showing changes in serum or pulmonary ACE2 levels"/>
 <result pre="however, there is limited evidence showing changes in serum or" exact="pulmonary" post="ACE2 levels (Patel and Verma, 2020; Zhang etÂ al.,"/>
 <result pre="2020c). In addition, serological, radiological, and histomorphological similarities of COVID-19-associated" exact="acute" post="respiratory distress syndrome (ARDS) and connective tissue disease-associated interstitial"/>
 <result pre="In addition, serological, radiological, and histomorphological similarities of COVID-19-associated acute" exact="respiratory" post="distress syndrome (ARDS) and connective tissue disease-associated interstitial lung"/>
 <result pre="serological, radiological, and histomorphological similarities of COVID-19-associated acute respiratory distress" exact="syndrome" post="(ARDS) and connective tissue disease-associated interstitial lung disease (CTD-ILD)"/>
 <result pre="COVID-19-associated acute respiratory distress syndrome (ARDS) and connective tissue disease-associated" exact="interstitial lung disease" post="(CTD-ILD) propose the postulation of triggering or simulating a"/>
 <result pre="acute respiratory distress syndrome (ARDS) and connective tissue disease-associated interstitial" exact="lung disease" post="(CTD-ILD) propose the postulation of triggering or simulating a"/>
 <result pre="respiratory distress syndrome (ARDS) and connective tissue disease-associated interstitial lung" exact="disease" post="(CTD-ILD) propose the postulation of triggering or simulating a"/>
 <result pre="in identified patients with autoantibodies may prevent the development of" exact="respiratory" post="failure. Promising Approved Drugs and Available Clinical Trials for"/>
 <result pre="(Table 1), but many drugs are discovered for a specific" exact="disease" post="and repurposed later for another disorder. FigureÂ 2 illustrates"/>
 <result pre="a cytochrome P450 and P-gp inhibitor HIV Oseltamivir Tamiflu Inhibits" exact="viral" post="neuraminidase and blocks the release of viral particles from"/>
 <result pre="Oseltamivir Tamiflu Inhibits viral neuraminidase and blocks the release of" exact="viral" post="particles from host cells Influenza Remdesivir â€&quot; Nucleotide analog"/>
 <result pre="inhibitor of RNA-dependent RNA polymerase (RdRp) Ebola virus Umifenovir Arbidol" exact="Viral" post="fusion inhibition with the targeted membrane Influenza,SARS-CoV Various well-known"/>
 <result pre="Inhibition translation of mRNA Macrolide antibiotic Doxycycline Doxylin, others Inhibition" exact="bacterial" post="protein synthesis Tetracycline antibiotic Chloroquine and hydroxychloroquine Aralen, Plaquenil,"/>
 <result pre="Quineprox, others Increase of lysosomal pH in antigen-presenting cells Malaria," exact="systemic" post="lupus erythematosus Nitazoxanide Alinia, Nizonide, and others Inhibition of"/>
 <result pre="others Increase of lysosomal pH in antigen-presenting cells Malaria, systemic" exact="lupus erythematosus" post="Nitazoxanide Alinia, Nizonide, and others Inhibition of the pyruvate:"/>
 <result pre="cycle Broad-spectrum antiparasitic LosartanValsartan Cozaar, others Competitive angiotensin II receptor" exact="type 1" post="antagonist Hypertension Tetrandrine â€&quot; Calcium channel blocker Hypertension Spironolactone"/>
 <result pre="LosartanValsartan Cozaar, others Competitive angiotensin II receptor type 1 antagonist" exact="Hypertension" post="Tetrandrine â€&quot; Calcium channel blocker Hypertension Spironolactone Aldactone, others"/>
 <result pre="receptor type 1 antagonist Hypertension Tetrandrine â€&quot; Calcium channel blocker" exact="Hypertension" post="Spironolactone Aldactone, others Potassium-sparing diuretic Hypertension Bromhexine Bisolvon, others"/>
 <result pre="â€&quot; Calcium channel blocker Hypertension Spironolactone Aldactone, others Potassium-sparing diuretic" exact="Hypertension" post="Bromhexine Bisolvon, others Increasing lysosomal activity Mucolytic Dornase alfa"/>
 <result pre="lysosomal activity Mucolytic Dornase alfa Pulmozyme Recombinant human deoxyribonuclease I" exact="Cystic" post="fibrosis Dexmedetomidine Precedex Selective alpha-2 adrenoceptor agonist Sedation Fluoxetine"/>
 <result pre="alfa Pulmozyme Recombinant human deoxyribonuclease I Cystic fibrosis Dexmedetomidine Precedex" exact="Selective" post="alpha-2 adrenoceptor agonist Sedation Fluoxetine Prozac, others Selective serotonin"/>
 <result pre="Dexmedetomidine Precedex Selective alpha-2 adrenoceptor agonist Sedation Fluoxetine Prozac, others" exact="Selective" post="serotonin reuptake inhibitor Antidepressant Immunosuppressors Ruxolitinib Jakafi, Jakavi JAK"/>
 <result pre="serotonin reuptake inhibitor Antidepressant Immunosuppressors Ruxolitinib Jakafi, Jakavi JAK inhibition" exact="Rheumatoid arthritis" post="Tocilizumab Actemra, RoActemra Interleukin-6 receptor antagonist Rheumatoid arthritis Eculizumab"/>
 <result pre="reuptake inhibitor Antidepressant Immunosuppressors Ruxolitinib Jakafi, Jakavi JAK inhibition Rheumatoid" exact="arthritis" post="Tocilizumab Actemra, RoActemra Interleukin-6 receptor antagonist Rheumatoid arthritis Eculizumab"/>
 <result pre="JAK inhibition Rheumatoid arthritis Tocilizumab Actemra, RoActemra Interleukin-6 receptor antagonist" exact="Rheumatoid arthritis" post="Eculizumab Soliris Monoclonal antibody against C5 Paroxysmal nocturnal hemoglobinuria,"/>
 <result pre="inhibition Rheumatoid arthritis Tocilizumab Actemra, RoActemra Interleukin-6 receptor antagonist Rheumatoid" exact="arthritis" post="Eculizumab Soliris Monoclonal antibody against C5 Paroxysmal nocturnal hemoglobinuria,"/>
 <result pre="receptor antagonist Rheumatoid arthritis Eculizumab Soliris Monoclonal antibody against C5" exact="Paroxysmal nocturnal hemoglobinuria," post="atypical hemolytic uremic syndrome, neuromyelitis optica Methylprednisolone Medrol, Meprolone,"/>
 <result pre="antagonist Rheumatoid arthritis Eculizumab Soliris Monoclonal antibody against C5 Paroxysmal" exact="nocturnal" post="hemoglobinuria, atypical hemolytic uremic syndrome, neuromyelitis optica Methylprednisolone Medrol,"/>
 <result pre="arthritis Eculizumab Soliris Monoclonal antibody against C5 Paroxysmal nocturnal hemoglobinuria," exact="atypical" post="hemolytic uremic syndrome, neuromyelitis optica Methylprednisolone Medrol, Meprolone, others"/>
 <result pre="Eculizumab Soliris Monoclonal antibody against C5 Paroxysmal nocturnal hemoglobinuria, atypical" exact="hemolytic uremic syndrome," post="neuromyelitis optica Methylprednisolone Medrol, Meprolone, others Inhibition of proinflammatory"/>
 <result pre="antibody against C5 Paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome," exact="neuromyelitis optica" post="Methylprednisolone Medrol, Meprolone, others Inhibition of proinflammatory cytokine production"/>
 <result pre="system disorders Budesonide Pulmicort, others Inhibition of proinflammatory cytokine production" exact="Asthma" post="Immunomodulators Camostat Foipan Inhibition of the transmembrane protease, serine"/>
 <result pre="Camostat Foipan Inhibition of the transmembrane protease, serine 2 enzyme" exact="Chronic" post="pancreatitis Interferons (IFN) IFN alfa-1b (Pegasys), IFN alfa-2b (Intron-A),"/>
 <result pre="Foipan Inhibition of the transmembrane protease, serine 2 enzyme Chronic" exact="pancreatitis" post="Interferons (IFN) IFN alfa-1b (Pegasys), IFN alfa-2b (Intron-A), IFN"/>
 <result pre="(Betaseron, Extavia) Initiation of JAK-STAT signaling cascades HBV, HCV, various" exact="autoimmune" post="disorders, and cancers Sargramostim Leukine Recombinant granulocyte macrophage colony-stimulating"/>
 <result pre="cancers Sargramostim Leukine Recombinant granulocyte macrophage colony-stimulating factor Non-Hodgkin lymphoma," exact="acute lymphocytic leukemia" post="Lenalidomide Revlimid Induces tumor cell apoptosis Multiple myeloma P-gp,"/>
 <result pre="Sargramostim Leukine Recombinant granulocyte macrophage colony-stimulating factor Non-Hodgkin lymphoma, acute" exact="lymphocytic leukemia" post="Lenalidomide Revlimid Induces tumor cell apoptosis Multiple myeloma P-gp,"/>
 <result pre="Leukine Recombinant granulocyte macrophage colony-stimulating factor Non-Hodgkin lymphoma, acute lymphocytic" exact="leukemia" post="Lenalidomide Revlimid Induces tumor cell apoptosis Multiple myeloma P-gp,"/>
 <result pre="colony-stimulating factor Non-Hodgkin lymphoma, acute lymphocytic leukemia Lenalidomide Revlimid Induces" exact="tumor" post="cell apoptosis Multiple myeloma P-gp, P-glycoprotein; HBV, hepatitis B"/>
 <result pre="lymphoma, acute lymphocytic leukemia Lenalidomide Revlimid Induces tumor cell apoptosis" exact="Multiple" post="myeloma P-gp, P-glycoprotein; HBV, hepatitis B virus; HCV, hepatitis"/>
 <result pre="acute lymphocytic leukemia Lenalidomide Revlimid Induces tumor cell apoptosis Multiple" exact="myeloma" post="P-gp, P-glycoprotein; HBV, hepatitis B virus; HCV, hepatitis C"/>
 <result pre="Revlimid Induces tumor cell apoptosis Multiple myeloma P-gp, P-glycoprotein; HBV," exact="hepatitis" post="B virus; HCV, hepatitis C virus. aProperties of repurposed"/>
 <result pre="apoptosis Multiple myeloma P-gp, P-glycoprotein; HBV, hepatitis B virus; HCV," exact="hepatitis C" post="virus. aProperties of repurposed drugs for COVID-19 are comprehensively"/>
 <result pre="and Candidate Treatments Before clinical manifestations for COVID-19, a significant" exact="viral" post="amplification occurs, which subsequently leads to mild symptoms. Later,"/>
 <result pre="occurs, which subsequently leads to mild symptoms. Later, at the" exact="end stage" post="of infection, severe symptoms are mostly due to the"/>
 <result pre="the inflammatory cell infiltration and inflammatory cytokine storm, which cause" exact="acute" post="lung injury, ARDS, and death (Zhang etÂ al., 2020c)."/>
 <result pre="Accordingly, the treatment strategy depends on the stage of the" exact="disease" post="or a combination therapy might be considered. Also, it"/>
 <result pre="by patients with COVID-19 based on positive inÂ vitro and" exact="limited" post="clinical data. In addition, azithromycin, a macrolide antibiotic, was"/>
 <result pre="of lopinavir/ritonavir combination therapy against COVID-19. Lopinavir is a human" exact="immunodeficiency" post="virus type 1 (HIV-1) protease inhibitor, and in a"/>
 <result pre="combination therapy against COVID-19. Lopinavir is a human immunodeficiency virus" exact="type 1" post="(HIV-1) protease inhibitor, and in a fixed-dose combination with"/>
 <result pre="concentrations, could block the main protease of SARS-CoV-1, and inhibits" exact="viral" post="replication (Ratia etÂ al., 2008). This combination is being"/>
 <result pre="but was later considered as a complementary treatment in cytokine-release" exact="syndrome" post="disease (Kotch etÂ al., 2019). Tocilizumab can diminish the"/>
 <result pre="was later considered as a complementary treatment in cytokine-release syndrome" exact="disease" post="(Kotch etÂ al., 2019). Tocilizumab can diminish the effect"/>
 <result pre="recombinant soluble ACE2 (hrsACE2) can block early stages of SARS-CoV-2" exact="infections" post="(Monteil etÂ al., 2020). ACE2 seems to be a"/>
 <result pre="between the lack of universal policies of Bacillus Calmette-Guerin (BCG)" exact="childhood" post="vaccination (Italy, Netherlands, the United States) and the severity"/>
 <result pre="severe COVID-19 who mostly progress to an ARDS condition: hypoxemic" exact="respiratory" post="failure associated with neutrophilia and neutrophil infiltration in the"/>
 <result pre="neutrophil infiltration in the lungs, thick mucus in bronchi, and" exact="bronchiectasis" post="(Pottecher etÂ al., 2020). Dornase alfa acts as a"/>
 <result pre="over 40 antiviral agents are accessible for the treatment of" exact="viral" post="infections. Unfortunately, the most commonly used antiviral drugs are"/>
 <result pre="(De Clercq and Li, 2016). Drug repurposing approaches related to" exact="infectious diseases" post="incorporate a variety of applications by harmonizing key bioinformatics"/>
 <result pre="target that could be repurposed in the combat against a" exact="viral" post="pathogen (Turanli et al., 2019). In addition to indisputable"/>
 <result pre="with compassionate use programs, particularly in the context of untreatable" exact="viral" post="diseases or pandemics. Furthermore, drug repurposing provides an alternative"/>
 <result pre="of data for a novel understanding of metabolic reprogramming in" exact="viral" post="infections, as well as the organic compounds with previously"/>
 <result pre="(Pizzorno etÂ al., 2019). In various instances, drug repurposing identifies" exact="formerly" post="undiscovered biomolecular networks, transforming them into novel pharmaceutical targets,"/>
 <result pre="a very low therapeutic molecule approval rate, and as such," exact="viral" post="diseases such as hepatitis C and HIV are still"/>
 <result pre="molecule approval rate, and as such, viral diseases such as" exact="hepatitis C" post="and HIV are still without a vaccine. In recent"/>
 <result pre="drug, proved its repurposing potential for the treatment of Zika" exact="infections" post="(Xu etÂ al., 2016). Another interesting candidate is chloroquine"/>
 <result pre="is chloroquine and its derivatives, which are normally indicated for" exact="malaria" post="and have been extensively discussed in terms of their"/>
 <result pre="a drug against that of another drug (i.e., drug-drug comparison)," exact="disease" post="(i.e., drug-disease comparison), or clinical phenotype by using high-throughput"/>
 <result pre="in the binding site of another molecule to generate a" exact="stable" post="complex. Existing information of a receptor target associated with"/>
 <result pre="complex. Existing information of a receptor target associated with a" exact="disease" post="enables researchers to inspect various potential drugs for a"/>
 <result pre="data types such as gene expression patterns, protein interactions, or" exact="disease" post="pathology (Greene and Voight, 2016). Finally, GWAS seek to"/>
 <result pre="among diseases treated by medicine, and observable characteristics of the" exact="disease" post="revealed by GWAS and therefore give rise to repurposing"/>
 <result pre="the main protease by virtue of its crucial role in" exact="viral" post="gene expression and replication. Taking this into account, Zhang"/>
 <result pre="In addition, inhibiting the function of this enzyme blocks the" exact="viral" post="life cycle. The absence of homologs in humans means"/>
 <result pre="function of this enzyme blocks the viral life cycle. The" exact="absence of" post="homologs in humans means that Mpro is an attractive"/>
 <result pre="of homologs in humans means that Mpro is an attractive" exact="non-toxic" post="target for antiviral drug design that is not prone"/>
 <result pre="resistance, might show effectiveness in developing robust treatment options for" exact="viral" post="infections (Kaufmann etÂ al., 2018). However, lack of data"/>
 <result pre="might show effectiveness in developing robust treatment options for viral" exact="infections" post="(Kaufmann etÂ al., 2018). However, lack of data of"/>
 <result pre="However, lack of data of the pathophysiology of the SARS-CoV-2" exact="infection" post="restrains the development of small molecule candidates based on"/>
 <result pre="potential to be repurposed (Gordon et al., 2020). Characterization of" exact="viral" post="evolution and the alterations in host cell metabolism through"/>
 <result pre="alterations in host cell metabolism through the use of single-cell" exact="viral" post="metagenomic studies might shed light on the mechanisms of"/>
 <result pre="viral metagenomic studies might shed light on the mechanisms of" exact="viral" post="infections, including determination of the molecular signatures associated with"/>
 <result pre="large-scale datasets will lead to reveal many mechanistic aspects of" exact="viral" post="infections yet to be resolved and will help to"/>
 <result pre="datasets will lead to reveal many mechanistic aspects of viral" exact="infections" post="yet to be resolved and will help to develop"/>
 <result pre="(the virus family that used to cause mild to moderate" exact="upper" post="respiratory tract illnesses) and each one of them was"/>
 <result pre="virus family that used to cause mild to moderate upper" exact="respiratory" post="tract illnesses) and each one of them was cause"/>
 <result pre="flaviviral infections: dengue, Zika and beyondNat. Rev. Drug Discov.16201756558628473729 BostP.GiladiA.LiuY.BendjelalY.XuG.DavidE.Blecher-GonenR.CohenM.MedagliaC.LiH.Host-viral" exact="infection" post="maps reveal signatures of severe COVID-19 patientsCell202010.1016/j.cell.2020.05.006 BrownA.S.PatelC.J.A review"/>
 <result pre="in adults hospitalized with severe COVID-19N. Engl. J. Med.38220201787179932187464 ChanJ.F.-W.YuanS.KokK.-H.ToK.K.-W.ChuH.YangJ.XingF.LiuJ.YipC.C.-Y.PoonR.W.-S.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="with severe COVID-19N. Engl. J. Med.38220201787179932187464 ChanJ.F.-W.YuanS.KokK.-H.ToK.K.-W.ChuH.YangJ.XingF.LiuJ.YipC.C.-Y.PoonR.W.-S.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751332007143 ChenW.LanY.YuanX.DengX.LiY.CaiX.LiL.HeR.TanY.DengX.Detectable 2019-nCoV viral"/>
 <result pre="coronavirus pneumonia in Wuhan, China: a descriptive studyLancet395202050751332007143 ChenW.LanY.YuanX.DengX.LiY.CaiX.LiL.HeR.TanY.DengX.Detectable 2019-nCoV" exact="viral" post="RNA in blood is a strong indicator for the"/>
 <result pre="the further clinical severityEmerging Microbes Infect.92020469473 CohnS.KutalekR.Historical parallels, Ebola virus" exact="disease" post="and cholera: understanding community distrust and social violence with"/>
 <result pre="Agents202010594932205204 GiacomelliA.PezzatiL.ContiF.BernacchiaD.SianoM.OreniL.RusconiS.GervasoniC.RidolfoA.L.RizzardiniG.Self-reported olfactory and taste disorders in patients with severe" exact="acute" post="respiratory coronavirus 2 infection: a cross-sectional studyClin. Infect. Dis.202010.1093/cid/ciaa330"/>
 <result pre="GiacomelliA.PezzatiL.ContiF.BernacchiaD.SianoM.OreniL.RusconiS.GervasoniC.RidolfoA.L.RizzardiniG.Self-reported olfactory and taste disorders in patients with severe acute" exact="respiratory" post="coronavirus 2 infection: a cross-sectional studyClin. Infect. Dis.202010.1093/cid/ciaa330 GorbalenyaA.E.Severe"/>
 <result pre="respiratory coronavirus 2 infection: a cross-sectional studyClin. Infect. Dis.202010.1093/cid/ciaa330 GorbalenyaA.E.Severe" exact="acute" post="respiratory syndrome-related coronavirusâ€&quot;The species and its viruses, a statement"/>
 <result pre="coronavirus 2 infection: a cross-sectional studyClin. Infect. Dis.202010.1093/cid/ciaa330 GorbalenyaA.E.Severe acute" exact="respiratory" post="syndrome-related coronavirusâ€&quot;The species and its viruses, a statement of"/>
 <result pre="discoveries into effective therapiesHum. Mol. Genet.252016R94R9827340225 GuanW.-j.NiZ.-y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.LiuL.ShanH.LeiC.-l.HuiD.S.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaNew Engl. J. Med.38220201708172032109013 HayM.ThomasD.W.CraigheadJ.L.EconomidesC.RosenthalJ.Clinical development success"/>
 <result pre="human neutralizing antibodies elicited by SARS-CoV-2 infectionNature202010.1038/s41586-020-2380-z KaufmannS.H.E.DorhoiA.HotchkissR.S.BartenschlagerR.Host-directed therapies for" exact="bacterial" post="and viral infectionsNat. Rev. Drug Discov.172018355628935918 KeiserM.J.SetolaV.IrwinJ.J.LaggnerC.AbbasA.I.HufeisenS.J.JensenN.H.KuijerM.B.MatosR.C.TranT.B.Predicting new molecular"/>
 <result pre="antibodies elicited by SARS-CoV-2 infectionNature202010.1038/s41586-020-2380-z KaufmannS.H.E.DorhoiA.HotchkissR.S.BartenschlagerR.Host-directed therapies for bacterial and" exact="viral" post="infectionsNat. Rev. Drug Discov.172018355628935918 KeiserM.J.SetolaV.IrwinJ.J.LaggnerC.AbbasA.I.HufeisenS.J.JensenN.H.KuijerM.B.MatosR.C.TranT.B.Predicting new molecular targets for"/>
 <result pre="for known drugsNature462200917518119881490 KilianskiA.MielechA.M.DengX.BakerS.C.Assessing activity and inhibition of Middle East" exact="respiratory" post="syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensorsJ.Â"/>
 <result pre="known drugsNature462200917518119881490 KilianskiA.MielechA.M.DengX.BakerS.C.Assessing activity and inhibition of Middle East respiratory" exact="syndrome" post="coronavirus papain-like and 3C-like proteases using luciferase-based biosensorsJ.Â Virol.872013119551196223986593"/>
 <result pre="coronavirusâ€&quot;induced lung injuryNat. Med.11200587587916007097 LawG.L.Tisoncik-GoJ.KorthM.J.KatzeM.G.Drug repurposing: a better approach for" exact="infectious disease" post="drug discovery?Curr. Opin. Immunol.25201358859224011665 LiW.MooreM.J.VasilievaN.SuiJ.WongS.K.BerneM.A.SomasundaranM.SullivanJ.L.LuzuriagaK.GreenoughT.C.Angiotensin-converting enzyme 2 is a"/>
 <result pre="lung injuryNat. Med.11200587587916007097 LawG.L.Tisoncik-GoJ.KorthM.J.KatzeM.G.Drug repurposing: a better approach for infectious" exact="disease" post="drug discovery?Curr. Opin. Immunol.25201358859224011665 LiW.MooreM.J.VasilievaN.SuiJ.WongS.K.BerneM.A.SomasundaranM.SullivanJ.L.LuzuriagaK.GreenoughT.C.Angiotensin-converting enzyme 2 is a"/>
 <result pre="the COVID-19 pandemicTrends Pharmacol. Sci.41202036338232291112 MonteilV.KwonH.PradoP.Hagelkru?ysA.WimmerR.A.StahlM.LeopoldiA.GarretaE.Hurtado del PozoC.ProsperF.Inhibition of SARS-CoV-2" exact="infections" post="in engineered human tissues using clinical-grade soluble human ACE2Cell1812020905913.e732333836"/>
 <result pre="pestisTrends Microbiol.24201619019726698952 PizzornoA.PadeyB.TerrierO.Rosa-CalatravaM.Drug repurposing approaches for the treatment of influenza" exact="viral" post="infection: reviving old drugs to fight against a long-lived"/>
 <result pre="replicationProc. Natl. Acad. Sci. U S A1052008161191612418852458 RotheC.SchunkM.SothmannP.BretzelG.FroeschlG.WallrauchC.ZimmerT.ThielV.JankeC.GuggemosW.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyNew Engl. J. Med.382202097097132003551"/>
 <result pre="contact in GermanyNew Engl. J. Med.382202097097132003551 SandersJ.M.MonogueM.L.JodlowskiT.Z.CutrellJ.B.Pharmacologic treatments for coronavirus" exact="disease" post="2019 (COVID-19): a reviewJAMA323202018241836 SanseauP.AgarwalP.BarnesM.R.PastinenT.RichardsJ.B.CardonL.R.MooserV.Use of genome-wide association studies"/>
 <result pre="by remdesivirViruses112019326 TuranliB.AltayO.BorÃ©nJ.TurkezH.NielsenJ.UhlenM.ArgaK.Y.MardinogluA.Systems biology based drug repositioning for development of" exact="cancer" post="therapySemin. Cancer Biol.201910.1016/j.semcancer.2019.09.020 TuranliB.ZhangC.KimW.BenfeitasR.UhlenM.ArgaK.Y.MardinogluA.Discovery of therapeutic agents for prostate"/>
 <result pre="TuranliB.AltayO.BorÃ©nJ.TurkezH.NielsenJ.UhlenM.ArgaK.Y.MardinogluA.Systems biology based drug repositioning for development of cancer therapySemin." exact="Cancer" post="Biol.201910.1016/j.semcancer.2019.09.020 TuranliB.ZhangC.KimW.BenfeitasR.UhlenM.ArgaK.Y.MardinogluA.Discovery of therapeutic agents for prostate cancer using"/>
 <result pre="of cancer therapySemin. Cancer Biol.201910.1016/j.semcancer.2019.09.020 TuranliB.ZhangC.KimW.BenfeitasR.UhlenM.ArgaK.Y.MardinogluA.Discovery of therapeutic agents for" exact="prostate cancer" post="using genome-scale metabolic modeling and drug repositioningEBioMedicine42201938639630905848 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and"/>
 <result pre="cancer therapySemin. Cancer Biol.201910.1016/j.semcancer.2019.09.020 TuranliB.ZhangC.KimW.BenfeitasR.UhlenM.ArgaK.Y.MardinogluA.Discovery of therapeutic agents for prostate" exact="cancer" post="using genome-scale metabolic modeling and drug repositioningEBioMedicine42201938639630905848 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and"/>
 <result pre="epidemiological and clinical features of the emerging 2019 novel coronavirus" exact="pneumonia" post="(COVID-19) implicate special control measuresJ.Â Med. Virol.92202056857632134116 WangY.ZhangD.DuG.DuR.ZhaoJ.JinY.FuS.GaoL.ChengZ.LuQ.Remdesivir in"/>
 <result pre="2019 novel coronavirus Infection: proposal of conventional serologic assays for" exact="disease" post="diagnosis and infection monitoring [Commentary/Review]J.Â Med. Virol.92202046446732031264 XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of"/>
 <result pre="Infection: proposal of conventional serologic assays for disease diagnosis and" exact="infection" post="monitoring [Commentary/Review]J.Â Med. Virol.92202046446732031264 XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of small-molecule inhibitors of"/>
 <result pre="monitoring [Commentary/Review]J.Â Med. Virol.92202046446732031264 XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of small-molecule inhibitors of Zika" exact="virus infection" post="and induced neural cell death via a drug repurposing"/>
 <result pre="[Commentary/Review]J.Â Med. Virol.92202046446732031264 XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of small-molecule inhibitors of Zika virus" exact="infection" post="and induced neural cell death via a drug repurposing"/>
 <result pre="implications for substrate binding and antiviral drug designJ.Â Virol.8220082515252718094151 YuP.ZhuJ.ZhangZ.HanY.HuangL.A" exact="familial" post="cluster of infection associated with the 2019 novel coronavirus"/>
 <result pre="binding and antiviral drug designJ.Â Virol.8220082515252718094151 YuP.ZhuJ.ZhangZ.HanY.HuangL.A familial cluster of" exact="infection" post="associated with the 2019 novel coronavirus indicating potential person-to-person"/>
 <result pre="anti-inflammatoryÂ drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): the experience of clinical immunologists from ChinaClin."/>
 <result pre="J. Med.3822020e3832268022 ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="with COVID-19 in Wuhan, China: a retrospective cohort studyLancet39520201054106232171076 ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="of probable bat originNature579202027027332015507 ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N.Â Engl. J. Med.382202072773331978945 ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.SARS-CoV-2 viral load"/>
 <result pre="patients with pneumonia in China, 2019N.Â Engl. J. Med.382202072773331978945 ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.SARS-CoV-2" exact="viral" post="load in upper respiratory specimens of infected patientsN.Â Engl."/>
 <result pre="in China, 2019N.Â Engl. J. Med.382202072773331978945 ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.SARS-CoV-2 viral load in" exact="upper" post="respiratory specimens of infected patientsN.Â Engl. J. Med.38220201177117932074444 Supplemental"/>
 <result pre="China, 2019N.Â Engl. J. Med.382202072773331978945 ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.SARS-CoV-2 viral load in upper" exact="respiratory" post="specimens of infected patientsN.Â Engl. J. Med.38220201177117932074444 Supplemental Information"/>
</results>
